Publikace
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline2019 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane2016 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?2016 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products2016 | Farmaceutická fakulta v Hradci Králové
- Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury2016 | Farmaceutická fakulta v Hradci Králové
- In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites2015 | Farmaceutická fakulta v Hradci Králové
- Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury2014 | Farmaceutická fakulta v Hradci Králové
Loading network view...
